Close Menu

NEW YORK (360Dx) – French diagnostic and theranostics firm Theradiag today said it has raised more than €4 million ($4.4 million) after issuing shares to "a specific category of persons."

Theradiag sold 1.7 million new shares at €2.30 per share. The shares were issued following an accelerated bookbuilding process, the firm said, adding the funds will go toward international development and the marketing of the company's autoimmunity, allergy, and theranostic products.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A new study finds that three dimensional facial scans may be able to aid in diagnosing rare genetic diseases.

The Lancet and the New England Journal of Medicine have retracted two COVID-19 papers due to concerns about the data used in their analyses.

Lawmakers plan to introduce a bill that aims to prevent the theft of US-funded research, according to the Wall Street Journal.

In Science this week: analysis of ancient Caribbean islanders' genomes suggests at least three waves of migration into the region,  DNA barcoding of microbial spores, and more.